Drug Trial Radar · NCT00123253
TH9507 in Patients With HIV-Associated Lipodystrophy
Last checked: Nov 20, 2026Latest source record: Nov 27, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
412
Actual
Start
Jun 2005
Primary completion
Nov 2006
Study completion Apr 2007
Sponsor
- Lead sponsor
- TheratechnologiesIndustry
- Sponsor type
- Industry
- First posted
- Jul 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation and loss of extremity and subcutaneous fat, in association with dyslipidemia and insulin resistance. Data from a previous randomized, placebo-controlled trial demonstrated that daily administration of 2mg TH9507, a growth hormone releasing factor (GRF), to HIV patients with an excess of abdominal fat accumulation for 12 weeks resulted in decreases in visceral adipose tissue (VAT) and trunk fat, with no significant changes in limb fat and subcutaneous adipose tissue (SAT). This study is aimed at further assessing the efficacy and safety of 2 mg TH9507 in a larger population of HIV patients treated with ART and experiencing an excess of abdominal fat accumulation.
Conditions
- HIV Infections
- Lipodystrophy
Interventions
TH9507Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Visceral adipose tissue (VAT)
Locations
42 sites in 2 countries. Site status is shown where the registry gives one.
UCLA School of Medicine
Los Angeles, California
Office of Dr. Michael Somero
Palm Springs, California
UCSD Medical Center
San Diego, California
Kaiser Permanente
San Francisco, California
AIDS Research Alliance
West Hollywood, California
Capital Medical Associates
Washington D.C., District of Columbia
Bach & Godofsky
Bradenton, Florida
Office of Dr. Gary Richmond
Fort Lauderdale, Florida
Care Resource Miami
Miami, Florida
Orlando Immunology Center
Orlando, Florida
Infectious Disease Associates
Sarasota, Florida
Treasure Coast Infectious Disease Consultant (TDIDC)
Vero Beach, Florida
AIDS Research Consortium Atlanta (ARCA)
Atlanta, Georgia
Northern Healthcare
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Indiana University Department of Medicine
Indianapolis, Indiana
Institute of Human Virology
Baltimore, Maryland
Johns Hopkins University School of Medicine
Baltimore, Maryland
Community Research Initiative of New England
Boston, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts
Tufts University School of Medicine
Boston, Massachusetts
Community Research Initiative of New England (CRI West)
Springfield, Massachusetts
Hennepin County Medical Centre
Minneapolis, Minnesota
AIDS Community Research Initiative of America
New York, New York
Bellevue Hospital Center New York University
New York, New York
St Luke's Roosevelt Hospital Centre
New York, New York
St Vincent Catholic Medical Centre
New York, New York
University of Cincinnati Medical Center
Cincinnati, Ohio
Fanno Creek Clinic, LLC
Portland, Oregon
Drexel University College of Medicine
Philadelphia, Pennsylvania
Central Texas Clinical Research
Austin, Texas
Dallas VA Medical Centre
Dallas, Texas
The University of Texas Medical School
Houston, Texas
Infectious Disease Physicians Inc.
Annandale, Virginia
Swedish Medical Center
Seattle, Washington
Southern Alberta Clinic
Calgary, Alberta, Canada
St-Paul's Hospital
Vancouver, British Columbia, Canada
Sunnybrook and Women College Health Sciences Centre
Toronto, Ontario, Canada
Windsor Regional Hospital
Windsor, Ontario, Canada
Clinique Médicale du Quartier Latin
Montreal, Quebec, Canada
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.